Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART study of as-needed rasburicase for prevention of tumor lysis syndrome
jRCT1051240144Recruiting
- Start
- Oct 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of rasburicase in tumor lysis syndrome (TLS), lymphosarcoma and acute lymphoblastic leukemia (ALL). Primary endpoint: Laboratory tumor lysis syndrome by day 7. Started Oct 2024; status: recruiting.
02
Drugs
rasburicase
03
Conditions
tumor lysis syndrome (TLS)lymphosarcomaacute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCT1051240144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051240144.